Barinthus Biotherapeutics (BRNS) Balance Sheet: Assets & Liabilities

Barinthus Biotherapeutics (BRNS) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Barinthus Biotherapeutics reported total assets of $98.17M and total liabilities of $23.88M. Shareholders' equity was $74.21M, down 43.0% from $130.13M a year earlier. Total debt stood at $11.28M against $70.46M in cash and short-term investments, a net cash position of $59.17M. That puts debt-to-equity at 0.15, compared with 0.09 a year earlier.

Barinthus Biotherapeutics Balance Sheet Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for Barinthus Biotherapeutics plc (BRNS) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Current Assets
Cash and Cash Equivalents	70.46	110.66	142.09	194.39	214.05	43.27	11.43
Cash & Short-Term Investments	70.46	110.66	142.09	194.39	214.05	43.27	11.43
Accounts Receivable	1.31	7.14	7.94	5.85	0.02	0.52	3.91
Inventory	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Current Assets	0.12	7.94	6.88	8.27	6.46	4.12	0.91
Total Current Assets	77.79	125.74	156.91	213.04	226.77	47.90	16.25
Non-Current Assets
Property, Plant & Equipment (Net)	5.16	11.76	19.40	15.71	9.09	2.77	2.79
Goodwill	0.00	0.00	12.21	12.21	12.63	0.00	0.00
Intangible Assets	14.29	21.95	25.11	28.27	31.43	0.00	0.00
Other Non-Current Assets	0.93	0.88	0.88	0.98	0.80	0.00	0.00
Total Non-Current Assets	20.38	34.59	57.60	57.16	53.95	2.77	2.79
Total Assets	98.17	160.33	214.51	270.21	280.72	50.67	19.04
Current Liabilities
Accounts Payable	0.35	2.47	1.60	3.75	2.42	4.67	3.89
Short-Term Debt	2.02	1.92	1.79	0.43	0.16	0.19	0.17
Accrued Liabilities	6.25	9.53	6.80	8.06	7.88	2.54	-
Deferred Revenue	1.40	1.74	0.00	0.00	0.18	0.00	0.27
Other Current Liabilities	6.25	7.11	9.21	8.06	7.88	2.78	1.42
Total Current Liabilities	10.02	15.66	12.60	12.24	11.16	7.64	5.75
Non-Current Liabilities
Long-Term Debt	9.26	10.09	11.19	8.34	6.54	46.17	1.61
Deferred Tax Liabilities	0.25	0.44	0.57	3.75	8.08	0.00	0.00
Other Non-Current Liabilities	4.35	4.45	3.15	6.42	10.46	0.00	33.76
Total Non-Current Liabilities	13.86	14.54	14.91	14.76	17.00	46.17	35.37
Total Liabilities	23.88	30.19	27.51	27.00	28.15	53.81	41.12
Stockholders' Equity
Common Stock	0.00	0.00	0.00	0.01	0.01	0.00	0.00
Retained Earnings	-304.09	-237.66	-176.59	-103.24	-108.59	-57.72	-37.89
Accumulated Other Comprehensive Income	-15.73	-25.87	-23.32	-33.46	-8.49	-1.24	-0.47
Additional Paid-in Capital	393.94	393.47	386.69	379.60	369.20	21.66	15.91
Minority Interest	0.08	0.11	0.21	0.31	0.44	0.39	0.37
Shares Outstanding	40.85	40.23	38.64	37.68	37.19	-	-
Total Stockholders' Equity	74.21	130.14	186.78	243.20	252.56	-3.54	-22.45
Total Liabilities & Equity	98.17	160.33	214.51	270.21	280.72	50.67	19.04

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Barinthus Biotherapeutics Balance Sheet

How much debt does Barinthus Biotherapeutics have?

Barinthus Biotherapeutics had total debt of $11.28M as of Dec 31, 2025, against $70.46M in cash and short-term investments. Its debt-to-equity ratio was 0.15. Total debt was $12.01M a year earlier.

What are Barinthus Biotherapeutics's total assets?

Barinthus Biotherapeutics reported total assets of $98.17M as of Dec 31, 2025, down 38.8% from $160.33M a year earlier. Total liabilities were $23.88M.

What is Barinthus Biotherapeutics's shareholders' equity?

Barinthus Biotherapeutics's shareholders' equity was $74.21M as of Dec 31, 2025, or about $1.82 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition